Global Female Sexual Dysfunction Treatment Market Report and Forecast 2023-2031

Global Female Sexual Dysfunction Market Report and Forecast 2023-2031

Global Female Sexual Dysfunction Market Outlook

The global female sexual dysfunction market value is anticipated to grow at a CAGR of 34.2% during the forecast period of 2023-2031 driven by the increasing awareness and acceptance of FSD as a medical condition across the globe.

Female Sexual Dysfunction Introduction

Female Sexual Dysfunction (FSD) is a medical condition that affects women's sexual health, causing physical or psychological issues that interfere with a woman's sexual desire, arousal, orgasm, and satisfaction. The causes of FSD can be multifactorial, including physical, psychological, and social factors such as hormonal imbalances, chronic diseases, relationship problems, stress, and cultural or religious beliefs.

FSD affects a significant proportion of women worldwide, and the condition often goes underdiagnosed and undertreated due to societal stigma, lack of awareness, and limited treatment options. However, the growing recognition of FSD as a medical condition has led to increased research and development of effective treatment options, including pharmacological and non-pharmacological interventions.

The global FSD treatment market is expected to grow significantly in the coming years due to increasing awareness and acceptance of FSD as a medical condition, growing healthcare expenditure, and rising demand for effective treatment options. However, the market also faces challenges such as the lack of well-established treatment options, high treatment costs, and limited insurance coverage, which may limit market growth.

Female Sexual Dysfunction Market Scenario

Female sexual dysfunction (FSD) is a common condition affecting a significant number of women worldwide. It refers to a range of sexual disorders that can have a negative impact on a woman's sexual satisfaction and overall quality of life. FSD can arise due to a variety of physical, psychological, and social factors, including hormonal imbalances, menopause, stress, anxiety, relationship problems, and certain medical conditions.

The market for FSD treatment options has been growing rapidly in recent years, with an increasing number of pharmaceutical and medical device companies developing products aimed at addressing this condition. However, despite the prevalence of FSD, it remains a largely underdiagnosed and undertreated condition, with many women either not seeking treatment or not receiving effective treatment.

The global FSD market is expected to continue to grow as more women become aware of the condition and seek out treatment options. However, the market also faces challenges, including a lack of understanding of the underlying causes of FSD, the limited effectiveness of some existing treatments, and the stigma and taboo surrounding sexual health issues. In response, there is a growing focus on developing more targeted and personalized treatments for FSD, as well as on increasing education and awareness around the condition.

Female Sexual Dysfunction Market Segmentations

Market Breakup by Type
  • Non-Hormonal Therapy
  • Hormonal Therapy
  • Others
Market Breakup by Age
  • 20-30 Years
  • 30-45 Years
  • Above 45 Years
Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Key Trends in the Female Sexual Dysfunction Market

Some key trends in the Female Sexual Dysfunction market are:
  • Increasing awareness and acceptance of Female Sexual Dysfunction as a medical condition among women and healthcare providers.
  • Development of new and effective treatments for Female Sexual Dysfunction, such as topical creams, injectables, and non-invasive therapies.
  • Growing demand for sexual wellness products and services, including educational resources, counselling, and sex therapy.
  • Expansion of the market to include more diverse and inclusive products and services that cater to different sexual orientations and gender identities.
  • Increasing investments in research and development to understand the underlying causes of Female Sexual Dysfunction and develop more targeted treatments.
  • Adoption of telemedicine and other digital technologies to provide convenient and confidential access to sexual healthcare services.
  • Rising prevalence of Female Sexual Dysfunction due to various factors such as aging, hormonal changes, medication use, and chronic health conditions.

Female Sexual Dysfunction Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • AMAG Pharmaceuticals Inc.
  • Emotional Brain BV
  • Sprout Pharmaceuticals, Inc.
  • Pivot Pharmaceuticals Inc.
  • Apricus Biosciences, Inc.
  • GlaxoSmithKline, Plc
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • Cipla Inc
  • Duchesnay Inc.
  • Novo Nordisk AS
*Please Note:* The report will be completed in 7 business days after order confirmation

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Female Sexual Dysfunction Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Female Sexual Dysfunction Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Female Sexual Dysfunction Epidemiology (2016-2031)
5.3 Europe Female Sexual Dysfunction Epidemiology (2016-2031)
5.4 Asia-Pacific Female Sexual Dysfunction Epidemiology (2016-2031)
5.5 Latin America Female Sexual Dysfunction Epidemiology (2016-2031)
5.6 Middle East & Africa Female Sexual Dysfunction Epidemiology (2016-2031)
6 Global Female Sexual Dysfunction Treatment Market Overview
6.1 Global Female Sexual Dysfunction Treatment Market Historical Value (2016-2022)
6.2 Global Female Sexual Dysfunction Treatment Market Forecast Value (2023-2031)
7 Global Female Sexual Dysfunction Treatment Market Landscape
7.1 Female Sexual Dysfunction Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Female Sexual Dysfunction Treatment: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Age
8 Female Sexual Dysfunction Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Female Sexual Dysfunction Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Female Sexual Dysfunction Treatment Market Segmentation
11.1 Global Female Sexual Dysfunction Treatment Market by Type
11.1.1 Market Overview
11.1.2 Non-Hormonal Therapy
11.1.3 Hormonal Therapy
11.1.4 Others
11.2 Global Female Sexual Dysfunction Treatment Market by Age
11.2.1 Market Overview
11.2.2 20-30 Years
11.2.3 30-45 Years
11.2.4 Above 45 Years
11.3 Global Female Sexual Dysfunction Treatment Market by Region
11.3.1 Market Overview
11.3.2 North America
11.3.3 Europe
11.3.4 Asia Pacific
11.3.5 Latin America
11.3.6 Middle East and Africa
12 North America Female Sexual Dysfunction Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Female Sexual Dysfunction Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Female Sexual Dysfunction Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Female Sexual Dysfunction Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Female Sexual Dysfunction Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 AMAG Pharmaceuticals Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Emotional Brain BV
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Sprout Pharmaceuticals, Inc.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Pivot Pharmaceuticals Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Apricus Biosciences, Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 GlaxoSmithKline, Plc
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Pfizer, Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Merck & Co., Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Cipla Inc
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Duchesnay Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Novo Nordisk AS
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
24 Female Sexual Dysfunction Treatment - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings